CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
Fireside Chat: Monday, April 24, 2023 at 9:30 am ET
H.C. Wainwright BioConnect Investor Conference
Fireside Chat: Tuesday, May 2, 2023 at 12:00 pm ET
Location: Nasdaq World Headquarters, New York, NY
The JMP Securities Life Sciences Conference
Fireside Chat: Tuesday, May 16, 2023 at 3:00 pm ET
Location: New York Hilton Midtown, New York, NY
A live webcast and archived replay of the fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.60 |
| Daily Change: | -0.14 -8.05 |
| Daily Volume: | 6,102,541 |
| Market Cap: | US$202.690M |
August 27, 2025 July 21, 2025 June 25, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
